股骨头坏死ARCO 3A期平片分期准确性及误分期原因分析

目的评估X线平片对股骨头坏死ARCO3A期分期的准确性,并分析其误分期的原因。方法回顾性分析2017年1月至2023年7月同期行髋关节正、蛙式位X线及CT检查,且髋关节CT分期为ARCO3A期的158例股骨头坏死患者,其中14例为双侧ARCO3A期,共计172例ARCO3A期股骨头坏死,F/M=67/91,平均年龄43.7±11.8岁。观察髋关节X线正、蛙式位图像进行ARCO分期并统计结果。结果髋关节X线分期为ARCO 3A期139例,误分期为ARCO 2期33例,准确率为80.8%;对照同期髋关节CT图像,X线误分期病例中未发现软骨下骨折6例(18.2%)、未发现坏死区骨折4例(12.1%)、未发现股骨头局限塌陷23例(69.7%)。结论X线对股骨头坏死ARCO 3A期分期的准确性高,但仍存在误分期的状况。在临床工作中,正位结合蛙式位,仔细观察关节面局部轻微不光整及软骨下、坏死区骨折等征象有助于提高X线平片对股骨头坏死ARCO3A期分期的准确性。

基于中日友好医院分型ARCOⅡ期股骨头坏死的自然塌陷病程

背景:股骨头坏死是骨科难治性疾病之一,不同分期、分型下的股骨头坏死自然塌陷病程影响着该病的进展及预后。目的:探究不同中日友好医院(China-Japan Friendship Hospital,CJFH)分型下国际骨循环研究协会(Association Research Circulation Osseous,ARCO)Ⅱ期股骨头坏死未塌陷患者5年内自然塌陷病程,并分析不同CJFH分型的股骨头塌陷率及塌陷风险。方法:回顾性选取2016年10月至2017年10月在西安交通大学附属红会医院门诊确诊为ARCOⅡ期股骨头坏死未塌陷的患者为研究对象,根据是否塌陷将患髋分为塌陷组(n=82)和未塌陷组(n=70),统计不同CJFH分型的股骨头塌陷风险以及5年内塌陷时间、塌陷数量和塌陷率,并绘制不同CJFH分型股骨头的Kaplan-Meier生存曲线图。结果与结论:①共纳入患者97例,152髋,随访期间有82髋塌陷,总塌陷率为53.9%,其中M型、C型、L1型、L2型和L3型塌陷率分别为0.0%,36.7%,51.4%,72.2%和77.8%,各组间比较差异有显著性意义(P<0.05);②在塌陷风险方面,L1型塌陷风险为C型的1.704倍(P>0.05),而L2型、L3型塌陷风险分别为C型的3.866倍、6.423倍(P<0.05);③在Kaplan-Meier生存曲线方面,ARCOⅡ期患者股骨头中位生存时间为3年,95%置信区间为2.885-3.471年,第1,3,5年股骨头生存率分别为65.1%(99/152),50.7%(77/152),46.1%(70/152);④结果表明,不同CJFH分型影响着ARCOⅡ期股骨头坏死患者的塌陷率,其中L3型患者塌陷率最高,L2型和L1型患者次之,C型患者塌陷率较低,M型患者无塌陷,这表明股骨头外侧柱的保留对股骨头坏死自然塌陷病程有重要意义。

金匮肾气丸辅治Ⅱ-Ⅲ期糖尿病肾病疗效观察

目的:观察金匮肾气丸辅治Ⅱ-Ⅲ期糖尿病肾病的临床疗效。方法:74例按照随机数字表法分为对照组与研究组各37例,两组均用达格列净和贝那普利治疗,研究组加用金匮肾气丸。结果:研究组总有效率与估算肾小球滤过率(eGFR)水平高于对照组(P<0.05),中医证候积分、血肌酐(SCR)、血尿素氮(BUN)、24h尿总量蛋白(TUP)和尿微量白蛋白/尿肌酐(UMA/UCR)以及空腹血糖(FBG)水平均低于对照组(P<0.05)。结论:金匮肾气丸辅治Ⅱ-Ⅲ期糖尿病肾病可提高疗效。

血清TAP、proGRP、cyfra21-1与Ⅲ~Ⅳ期NSCLC新辅助化疗疗效及预后的关系

目的探讨血清肿瘤异常蛋白(TAP)、胃泌素释放肽前体(proGRP)、细胞角蛋白19片段(cyfra21-1)与Ⅲ~Ⅳ期非小细胞肺癌(NSCLC)新辅助化疗(NCT)疗效及预后的关系。方法选取100例Ⅲ~Ⅳ期NSCLC患者为研究对象,所有患者均采用NCT治疗,根据疗效将患者分为有效组和无效组,比较不同疗效患者化疗前后TAP、proGRP、cyfra21-1水平,分析化疗后TAP、proGRP、cyfra21-1水平对NSCLC患者NCT疗效的评估价值。所有患者均随访1年,分析化疗后TAP、proGRP、cyfra21-1表达水平与预后的关系。结果化疗后,有效组TAP、proGRP、cyfra21-1水平低于无效组(P<0.05)。ROC曲线结果显示,TAP评估NSCLC患者NCT疗效的AUC和截点值分别为0.739、178.18μm 2,proGRP评估NSCLC患者NCT疗效的AUC和截点值分别为0.810、52.21 ng/L,cyfra21-1评估NSCLC患者NCT疗效的AUC和截点值分别为0.775、7.70μmol/L,联合评估NSCLC患者NCT疗效的AUC为0.913,高于单项诊断(P<0.05)。TAP、proGRP、cyfra21-1高表达患者的1年生存率均低于低表达患者(P<0.05)。结论TAP、proGRP、cyfra21-1联合评估Ⅲ~Ⅳ期NSCLC患者NCT疗效具有较高价值,且其均与NSCLC患者预后密切相关。

股骨头坏死ARCO 2期CT征象对新发骨质吸收区预测价值分析

目的 分析股骨头坏死ARCO 2期CT征象对新发骨质吸收区的预测价值。方法 回顾性分析2011年至2017年进行髋关节CT检查国际骨微循环研究协会(Association Research Circulation Osseous,ARCO)2期的股骨头坏死94例患者(F/M=24/70,中位年龄41.0(33.3-54.0)岁)。评估初次CT检查的征象,包括骨质坏死的位置、ARCO分期范围、密度和增生反应区的形态。根据随访3年有无骨质吸收区将病例分为新发骨质吸收组和无骨质吸收组。对比两组CT征象的差异,并分析单一和CT征象组合对新发骨质吸收区的预测价值。结果 骨质坏死位于中外侧柱或内中外侧柱、坏死范围大于30%及增生反应区呈横行在新发骨质吸收组显著多于无骨质吸收组。CT征象组合2(骨质坏死位置、坏死范围及增生反应区呈横行形态)对新发骨质吸收区的预测价值最大,曲线下面积(Area Under Curve,AUC)为0.79,敏感性和特异性分别为89.13%和62.50%,阈值>1。结论 如果骨质坏死区位于中外侧柱或内中外侧柱,坏死范围大于30%,且增生反应区呈横行,则易发生骨质吸收区,应密切随访。

Ⅲ_a期非小细胞肺癌术后辅助放疗开始时间对远期生存的影响

目的:分析Ⅲ_a期非小细胞肺癌术后辅助放疗开始时间与手术间隔的时间对患者远期生存的影响。方法:回顾性分析我院收治的42例Ⅲ_a期非小细胞肺癌术后放疗患者的临床资料,其中卡氏评分60～90分;男性22例,女性20例;年龄30～74岁,中位年龄55岁;鳞癌13例,腺癌23例,其它6例;切缘阳性17例,阴性25例;术后放疗开始时间与手术间隔的时间13～120天,放射治疗采用常规放疗或三维适形放疗,放疗剂量40～66 Gy,所有患者均行2～6疗程以铂类为主的双药联合化疗。结果:术后放疗开始时间与手术间隔时间长者(43～120天) 5年生存率好于间隔时间短者(13～42天)(P=0. 040),手术与术后放疗开始时间的间隔对手术切缘阳性者的5年生存率影响差异无统计学意义(P=0. 067)。结论:对Ⅲ_a期非小细胞肺癌患者,术后早放疗并不能提高患者的生存,若术后计划行放化疗,放疗在手术后1个半月后开始可能效果更好。

165例Ⅲ_a期非小细胞肺癌以手术为主的综合治疗

目的 探讨晚期肺癌的疗效。 方法 165例Ⅲa期非小细胞肺癌以手术为主,配合化疗、放疗的综合治疗。 结果 165例以手术为主的综合治疗组与98例非手术组一、三、五年生存率比较,分别为679%、385%、238%和408%、125%、62%,前者明显高于后者,以手术为主的综合治疗组与非手术组一、三、五年生存率之间差异有显著性(P<0025)。 结论 Ⅲa期非小细胞肺癌病人应不失时机选择以手术为主的综合治疗。

髓芯减压联合含骨形态发生蛋白打压植骨术治疗ARCO ⅢA期股骨头坏死的中期疗效

目的:探讨髓芯减压联合含骨形态发生蛋白(BMP)的打压植骨术治疗ARCOⅢA期的非创伤性股骨头坏死(ONFH)的中期效果,并分析影响股骨头长期存活的非疾病相关因素。方法:回顾性分析2013年6月至2017年12月因ONFH接受10 mm髓芯减压联合含BMP的打压植骨术治疗的23例患者。其中,男20例24髋,女3例3髋;年龄20~50岁,平均(35.2±9.2)岁;酒精致ONFH 20髋,特发性ONFH 7髋。患髋均为ARCOⅢA期,采用Harris髋关节评分和百分法评估疗效。结果:23例患者随访12~90个月,平均(54.5±17.4)个月。至末次随访,4例5髋行髋关节置换术。术后和末次随访时Harris髋关节评分(Z=-17.934,P<0.001;Z=-7.986,P<0.001)和百分法评分(Z=-16.514,P<0.001;Z=-4.225,P<0.001)均较术前提高,差异具有统计学意义。术前所有患髋评分等级均为差;末次随访时Harris髋关节评估:优0髋、良3髋、可9髋、差15髋,百分法评估:优0髋、良6髋、可9髋、差12髋,分别有12、15髋评分等级较术前提升1~2个等级,在评分等级为差的患髋中,除髋关节置换者,所有患髋临床功能均较术前好转。总体好转率81.5%。结论:对ARCOⅢA期的非创伤性ONFH患者,髓芯减压联合含BMP的打压植骨术可有效缓解临床疼痛症状,并一定程度延缓影像学进展,中期效果满意。

ARCO 2/3期股骨头坏死骨质吸收区MR影像评估

目的分析MR对ARCO2/3期股骨头坏死骨质吸收区的检出率及骨质吸收区MR特征,并探讨骨质吸收区不同MR信号可能的病理基础。方法回顾性分析2015年1月至2022年10月就诊于骨科并行MR检查的312例ARCO 2/3期股骨头坏死病例,最终纳入41例,男/女=29/12,其中5例为双侧股骨头坏死,共46例股骨头坏死。根据骨质吸收区T2WI信号特点将病例分为两组,组1-T2WIⅠ型信号(等、稍高信号),组2-T2WIⅡ型信号(高信号)。评估并比较两组间骨质吸收区及相关CT/MR征象。结果MR检出骨质吸收区的敏感性为70.6%,特异性为100%。组2骨质吸收区的数量、ADC值、骨髓水肿分级以及骨质吸收区是否与软骨下骨折相连的几率大于组1,组2骨质吸收区的密度低于组1。结论MR检出骨质吸收区有良好的敏感性和极高的特异性。骨质吸收区T2WIⅠ型信号可能混淆于骨髓水肿中,应仔细甄别;骨质吸收区T2WIⅡ型信号更常伴软骨下骨折和大范围骨髓水肿,可能提示破坏性修复,应密切随访、及时干预。

游离髂骨瓣联合带血管蒂大转子骨瓣移植对中青年ARCOⅢ期股骨头坏死患者的保髋作用

背景:临床上经常采用单纯游离髂骨瓣移植伴或者不伴带血管大转子骨瓣移植治疗中青年ARCOⅢ期非创伤性股骨头坏死患者,但以上2项术式的疗效优势尚不十分明确。目的:比较游离髂骨瓣与其联合带血管蒂大转子骨瓣移植治疗中青年ARCOⅢ期股骨头坏死患者的临床疗效。方法:选择2009年1月至2013年11月于广州中医药大学第一附属医院行髂骨瓣联合带血管蒂大转子骨瓣移植(A组)与游离髂骨瓣移植(B组)的ARCOⅢ期股骨头坏死患者,年龄18-45岁。2组患者对治疗方案均知情同意,且得到医院伦理委员会批准。记录2组患者术口长度、住院时间、手术时间及出血量,比较组间ARCOⅢ期各亚型术前及末次随访Harris评分及疼痛目测类比评分,并统计髋关节优良率及保髋率。结果与结论:(1)共纳入71例患者(A组37例42髋,B组34例38髋),随访3.5-7年;(2)A组手术时间和术中出血量均大于B组,差异有显著性意义(P <0.05);(3)组内比较,2组术后末次随访ARCOⅢ期各亚型Harris评分及目测类比评分均较术前明显改善;组间比较,A组ARCOⅢb、c型患者术后髋关节Harris评分及目测类比评分均优于B组,差异均有显著性意义(P <0.05);2组ARCOⅢa期患者间Harris评分及目测类比评分差异无显著性意义(P> 0.05);(4)A、B组保髋率分别为91%和74%,差异有显著性意义(Z=3.9,P <0.05);据Harris评分结果,A、B组髋关节优良率分别为82%和75%;(5)2组患者术后均未出现严重并发症;(6)结果表明,游离髂骨瓣伴或不伴带血管蒂大转子骨瓣移植均为治疗中青年ARCOⅢ期股骨头坏死患者的有效方法,能明显改善髋关节功能并缓解疼痛,但前者治疗ARCOⅢ期b、c型股骨头坏死更具优势。

Prognostic and predictive significance of MSI in stages Ⅱ/Ⅲ colon cancer

In colon cancer,classic disease staging remains the key prognosis and treatment determinant.Although adjuvant chemotherapy has an established role in stageⅢcolon cancer patients,in stageⅡit is still a subject of controversy due to its restriction to a small subgroup of patients with high-risk histopathologic features.Patients with stageⅡtumors form a highly heterogeneous group,with five-year relative overall survival rates ranging from 87.5%(ⅡA)to 58.4%(ⅡC).Identifying those for whom adjuvant chemotherapy would be appropriate and necessary has been challenging,and prognostic markers which could serve in the selection of patients more likely to recur or benefit from adjuvant chemotherapy are eagerly needed.The stronger candidate in this category seems to be microsatellite instability(MSI).The recently reported European Society for Medical Oncology guidelines suggest that MSI should be evaluated in stageⅡcolorectal cancer patients in order to contribute in treatment decisionmaking regarding chemotherapy administration.Thehypothetical predictive role of MSI regarding its response to 5-fluorouracil-based adjuvant chemotherapy has proven a much more difficult issue to address.Almost every possible relation between MSI and chemotherapy outcome has been described in the adjuvant colon cancer setting in the international literature,and the matter is far from being settled.In this current report we critically evaluate the prognostic and predictive impact of MSI status in patients with stageⅡand stageⅢcolon cancer patients.

Macroscopic appearance of TypeⅣand giant Type Ⅲ is a high risk for a poor prognosis in pathological stage Ⅱ/Ⅲ advanced gastric cancer with postoperative adjuvant chemotherapy

AIM To evaluate whether a high risk macroscopic appearance(Type Ⅳ and giant Type Ⅲ) is associated with a dismal prognosis after curative surgery, because its prognostic relevance remains elusive in pathological stage Ⅱ/Ⅲ(p Stage Ⅱ/Ⅲ) gastric cancer.METHODS One hundred and seventy-two advanced gastric cancer(defined as pT2 or beyond) patients with p Stage Ⅱ/Ⅲ who underwent curative surgery plus adjuvant S1 chemotherapy were evaluated, and the prognostic relevance of a high-risk macroscopic appearance was examined. RESULTS Advanced gastric cancers with a high-risk macroscopic appearance were retrospectively identified by preoperative recorded images. A high-risk macroscopic appearance showed a significantly worse relapse free survival(RFS)(35.7%) and overall survival(OS)(34%) than an average risk appearance(P = 0.0003 and P < 0.0001, respectively). A high-risk macroscopic appearance was significantly associated with the 13^(th) Japanese Gastric Cancer Association(JGCA) pT(P = 0.01), but not with the 13^(th) JGCA pN. On univariate analysis for RFS and OS, prognostic factors included 13^(th) JGCA p Stage(P < 0.0001)and other clinicopathological factors including macroscopic appearance. A multivariate Cox proportional hazards model for univariate prognostic factors identified highrisk macroscopic appearance(P = 0.036, HR = 2.29 for RFS and P = 0.021, HR = 2.74 for OS) as an independent prognostic indicator. CONCLUSION A high-risk macroscopic appearance was associated with a poor prognosis, and it could be a prognostic factor independent of 13^(th) JGCA stage in p Stage Ⅱ/Ⅲ advanced gastric cancer.

Stage Ⅲ should be subclassified into Stage ⅢA and ⅢB in the American Joint Committee on Cancer(8^(th) Edition) staging system for pancreatic cancer

AIM To ascertain the prognostic role of the T4 and N2 category in stage Ⅲ pancreatic cancer according to the 8 th edition of the American Joint Committee on Cancer(AJCC) classification.METHODS Patients were collected from the Surveillance Epidemiology and End Results(SEER) database(2004-2013) and were divided into three groups: T(1-3)N2, T4 N(0-1), and T4 N2. Overall survival(OS) and disease-specific survival(DSS) of patients were evaluated by the Kaplan-Meier method. RESULTS For the first time, we found a significant difference in OS and DSS between T(1-3)N2/T4 N(0-1) and T4 N2 butnot between T(1-3)N2 and T4 N(0-1). A higher grading correlated with a worse prognosis in the T(1-3)N2 and T4 N2 groups.CONCLUSION Patients with stage T4 N2 had a worse prognosis than those with stage T(1-3)N2/T4 N(0-1) in the 8 th edition AJCC staging system for pancreatic cancer. We recommend that stage Ⅲ should be subclassified into stage ⅢA [T(1-3)N2/T4 N(0-1)] and stage ⅢB(T4 N2).

Effect of TCM Combined with Chemotherapy on Immune Function and Quality of Life of Patients with Non-small Cell Lung Cancer inStage Ⅲ-Ⅳ

Objective: To observe and compare the effect of traditional Chinese medicine (TCM) combined with chemotherapy (CT) on immune function and quality of life (QOL)of patients with non-small cell lung cancer (NSCLC) in stage Ⅲ-Ⅳ. Methods: One hundred cases with stage Ⅲ-Ⅳ NSCLC were randomly divided into two groups. The treated group (n=50) received CT combined with TCM, and the control group received CT alone. The percentage of T lymphocyte subset in peripheral blood and the change of natural killer (NK) cell count were observed after treatment. The QOL and tolerance of CT were also compared between the two groups after treatment. Results: In the treated group, CD3 cell count, CD4 cell count, CD4/ CDg ratio and NK cell activity were higher than those in control group, while CD8 cell count in the treated group was lower than that in the control group (P<0.05), and QOL and tolerance of CT in the treated group were also better (P<0.05). Conclusion: TCM combined with CT could raise the patients' ability in tolerating CT in stage Ⅲ-ⅣNSCLC.

Effect of Tongluo Shenggu Prescription on ARCO Stage Ⅱ non-traumatic femoral head necrosis: A prospective study

Objective:To observe the clinical results and therapeutic characteristics of Tongluo Shenggu Decoction in the treatment of ARCOⅡnon-traumatic femoral head necrosis.Methods:120 patients with ARCOⅡnon-traumatic femoral head necrosis from January 2016 to January 2017 were studied by prospective matched and controlled design.60 cases in the treatment group were treated with Tongluo Shenggu Formula.The control group(60 cases)received high energy extracorporeal shock wave therapy.The imaging stability rate,Harris score and SF-36 score were used as clinical efficacy indicators,followed up for 24 months,and the follow-up results were statistically analyzed.Results:Among the 120 patients,5 fell off and the rest were followed up.The imaging stability rate is heavy.The imaging stability rate of the patients in the treatment group is 78.95%,while that in the control group is 72.41%.The two groups have the same stability rate(P>0.05).In Harris score,the Harris score of the patients in the treatment group was 92.678.45 points,significantly higher than that of the control group(80.3924.65 points),the difference was statistically significant(p<0.05),and the pain degree,joint function and joint deformity score of the treatment group were better than those of the control group(p<0.05).In the SF-36 score,the scores of physiological function,physiological function,physical pain,overall health,social function and emotional function in the treatment group were significantly higher than those in the control group,the difference was statistically significant(p<0.05).the incidence of adverse events in the treatment period of the two groups was lower and the patients could relieve themselves in the later stage.Conclusion:Tongluo Shenggu prescription has definite curative effect in treating ARCOⅡnon-traumatic femoral head necrosis,especially in improving hip joint function,relieving hip joint pain and improving quality of life.To observe the clinical results and therapeutic characteristics of Tongluo Shenggu Decoction in the treatment of ARCOⅡnon-traumatic femoral head necrosis.Methods:120 patients with ARCOⅡnon-traumatic femoral head necrosis from January 2016 to January 2017 were studied by prospective matched and controlled design.60 cases in the treatment group were treated with Tongluo Shenggu Formula.The control group(60 cases)received high energy extracorporeal shock wave therapy.The imaging stability rate,Harris score and SF-36 score were used as clinical efficacy indicators,followed up for 24 months,and the follow-up results were statistically analyzed.Results:Among the 120 patients,5 fell off and the rest were followed up.The imaging stability rate is heavy.The imaging stability rate of the patients in the treatment group is 78.95%,while that in the control group is 72.41%.The two groups have the same stability rate(P>0.05).In Harris score,the Harris score of the patients in the treatment group was 92.678.45 points,significantly higher than that of the control group(80.3924.65 points),the difference was statistically significant(p<0.05),and the pain degree,joint function and joint deformity score of the treatment group were better than those of the control group(p<0.05).In the SF-36 score,the scores of physiological function,physiological function,physical pain,overall health,social function and emotional function in the treatment group were significantly higher than those in the control group,the difference was statistically significant(p<0.05).the incidence of adverse events in the treatment period of the two groups was lower and the patients could relieve themselves in the later stage.Conclusion:Tongluo Shenggu prescription has definite curative effect in treating ARCOⅡnon-traumatic femoral head necrosis,especially in improving hip joint function,relieving hip joint pain and improving quality of life.

Unresectable stage Ⅲ non-small-cell lung cancer: Have we made any progress?

Lung cancer is responsible for the most cancer deaths worldwide with an incidence that is still rising. One third of patients have unresectable stage ⅢA or stage ⅢB disease. The standard of care for locally advanceddisease in patients with good performance status consists of combined modality therapy in particular concurrent chemoradiotherapy. But despite a lot of efforts done in the past, local control and survival of patients with unresectable stage Ⅲ non-small-cell lung cancer(NSCLC) remains poor. Improving outcomes for patients with unresectable stage Ⅲ NSCLC has therefore been an area of ongoing research. Research has focused on improving systemic therapy, improving radiation therapy or adding a maintenance therapy to consolidate the initial therapy. Also implementation of newer targeted therapies and immunotherapy has been investigated as well as the option of prophylactic cranial irradiation. This article reviews the latest literature on improving local control and preventing distant metastases. It seems that we have reached a plateau with conventional chemotherapy. Radiotherapy dose escalation did not improve outcome although increasing radiation dose-intensity with new radiotherapy techniques and the use of newer agents, e.g., immunotherapy might be promising. In the future well-designed clinical trials are necessary to prove those promising results.

Role of radiation therapy in the management of stage Ⅲ non-small cell lung cancers: current status and controversies

The treatment of stage Ⅲ non-small cell lung cancer(NSCLC) consisting of the heterogeneous stage subsets remains a challenge. Overall, it has been gradually recognized that radiation therapy(RT) plays a crucial role in the management of stage Ⅲ NSCLC. One superior sulcus tumors are the subset for which the trimodality treatments are clearly preferred. One subset of stage Ⅲ NSCLC has a minimal disease burden with microscopic p N2 disease or with discrete p N2 involvement identified preoperatively, thus technically could undergo a surgical resection. For the incidentally found p N2 disease after complete surgery(ⅢA-1, ⅢA-2), the value of postoperative radiotherapy(PORT) has been recognized by a reassessment based on new data. However, doubt persists regarding how to define the clinical target volume for PORT. For the discrete p N2 involvement identified preoperatively(a selected part of ⅢA-3), induction chemoradiation therapy(CRT) before surgery may yield a survival advantage, although the phase Ⅲ randomized trials in this issue are not conclusive. The other major subset of stage Ⅲ NSCLC is the infiltrative stage Ⅲ NSCLC with N2 or N3 nodal disease(ⅢA-3, ⅢA-4, and ⅢB), for which concurrent CRT is considered as the current standard of care. The potential role of radiation dose escalation/acceleration has been proposed; however, the optimal dose fractionation remains an important unresolved question. Additionally, the role of prophylactic cranial irradiation for stage Ⅲ patients with high risk of brain metastasis is worth of further assessment. Moreover, how to integrate molecular targeted therapy with RT, as well as whether they had a role in stage Ⅲ diseases, are other controversies actively under study in ongoing trials. This review specifically describes the updated role of RT in multimodal approach to treat stage Ⅲ NSCLC and the controversies regarding these results in various situations.

Bushen Huoxue method combined with ACEI/ARB in treating diabetic kidney disease (stage Ⅲ):A meta-analysis and trial sequential analysis

Objective:To evaluate the efficiency of Bushen Huoxue method with ACEI/ARB in treating diabetic kidney disease(stageⅢ).Methods:A total of 8 major electronic databases(CNKI,WanFang,VIP,Sinomed,Pubmed,Embase,Cochrane Liberary,Web of Science)were retrieved since the establishment of the database to October 9,2019.Two reviewers extracted data,and assessed the methodological quality of the included studies.The analysis was made by Stata 15.0 and TSA 0.9 softwares.Results:A total of 10 RCT studies were obtained,including 711 patients with diabetic kidney disease of stageⅢ.Meta-analysis showed that the method of Bushen Huoxue with ACEI/ARB could reduce UAER[WMD=-31.24,95%CI(-42.98,-19.51)],β2-GM[WMD=-92.95,95%CI(-166.05,-19.85)],LDL-C[WMD=-0.19,95%CI(0.19,-0.30)].However,there were no significant effect for HbAlc[WMD=-0.08,95%CI(-0.17,-0.00)],Scr[WMD=-12.96,95%CI(-39.82,13.90)],BUN[WMD=-0.14,95%CI(-0.44,0.17)].The result of TSA indicated that the method of Bushen Huoxue with ACEI/ARB was effective in the treatment of diabetic kidney disease of stageⅢ.Conclusion:The study show that the method of Bushen Huoxue with ACEI/ARB can reduce urinary protein,renal tubular injury and LDL-C in patients with diabetic kidney disease of stageⅢ,and had no effect on HbAlc and renal function.But the conclusion of this study needs further research of high quality.

Yiqi Huoxue Decoction in the treatment of Qi and yin deficiency and stasis type diabetic nephropathy in stageⅢ and its effect on VEGF and TGF-β1

Objective:To observe the efficacy of Yiqi Huoxue Decoction in the treatment of patients with diabetic nephropathy(DN)stageⅢwith qi and yin deficiency and stasis and its effects on vascular endothelial growth factor(VEGF)and transforming growth factor-β(TGF-β1).Methods:Sixty patients with stage DN of Qi-yin deficiency and stasis type DN who were treated in the Endocrinology Department of the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine from September 2018 to December 2019 were selected as the research subjects.The remainder method was used to divide them into 30 cases in the observation group and 30 cases in the control group.Patients in both groups were referred to the guidelines and expert consensus for general treatment of DN(hypogl-ycemic,antihypertensive,lipid-lowering,etc.).The control group was given pancreatic kallikrein enteric-coated tablets orally once,120U,3 times a day,and the observation group was given The traditional Chinese medicine Yiqi Huoxue Decoction was taken orally,one dose daily,twice a day in the morning and evening;the two groups intervened continuously for 8 weeks.Detect blood FPG,PBG,HbA1c,β2-MG,BUN,SCr,VEGF,TGF-β1,and urine mALB and UACR levels before and after treatment,and calculate eGFR before and after treatment in both groups;observe changes in TCM syndrome scores in the two groups,Compare its clinical efficacy.Results:After 8 weeks of treatment,the total clinical effective rate of patients in the observation group was 93.3%,which was significantly different from the control group of 76.6%(P<0.05);the TCM syndrome scores in the observation group were significantly lower than those before treatment and in the control group(P<0.05);The levels of FPG,HbA1c,PPG,mALB,β2-MG,UACR,VEGF,and TGF-β1 in the observation group were significantly lower than those in the control group,with significant differences(P<0.05).The levels of SCr and BUN in the observation group were significantly lower.Compared with before treatment,eGFR increased,but there was no signi-ficant difference(P>0.05).Conclusion:Yiqi Huoxue Decoction for the treatment of patients with DN typeⅢqi-yin deficiency and stasis type,not only helps to lower blood sugar levels,improve TCM syndromes,but also can reduce early renal damage,reduce urine albumin,and delay kidney function It may be further worsened and has better safety.The mechanism may be related to reducing the levels of VEGF and TGF-β1,thereby delaying the fibrosis of tubulointerstitial scar and inhibi-ting glomerular capillary sclerosis.

基于病因和国际骨微循环研究协会分期的股骨头坏死患者骨代谢水平研究

背景:目前缺乏大样本研究对不同病因、分期的股骨头坏死患者的骨代谢水平进行分析,这不利于制定更优的促坏死修复策略。目的:研究不同病因、国际骨微循环研究协会(ARCO)分期股骨头坏死患者的骨代谢水平。方法:回顾性纳入股骨头坏死的患者401例作为试验组,81例健康体检者作为对照组。试验组按照病因不同分为激素性股骨头坏死、酒精性股骨头坏死和创伤性股骨头坏死3组,并按ARCO分期的不同分为Ⅱ期/Ⅲ期/Ⅳ期。收集所有受试者的7项骨代谢相关指标,包括骨代谢调控激素25-羟基维生素D,骨转换标志物Ⅰ型前胶原N末端前肽、β-胶原降解产物、骨钙素N端中分子片段,骨代谢一般生化标记血清Ca、P、碱性磷酸酶。比较各组受试者的骨代谢水平,并应用二元Logistic回归分析与股骨头坏死发病相关的独立因素。结果与结论:①与对照组比较,试验组患者的β-胶原降解产物、Ⅰ型前胶原N末端前肽、骨钙素N端中分子片段、血清P、碱性磷酸酶水平均显著升高(均P<0.05);②以是否发病为结局,应用二元Logistic回归分析得出β-胶原降解产物、Ⅰ型前胶原N末端前肽、骨钙素N端中分子片段是与股骨头坏死发病相关的独立因素;③不同病因3组患者的β-胶原降解产物、Ⅰ型前胶原N末端前肽水平均高于正常参考值;酒精性股骨头坏死组患者的25-羟基维生素D、血清Ca水平均高于其他2组(P<0.05);激素性股骨头坏死、创伤性股骨头坏死组患者的25-羟基维生素D水平均低于正常值;④ARCOⅡ、Ⅲ、Ⅳ期股骨头坏死患者的7项骨代谢指标水平比较差异均无显著性意义(均P>0.05),但3组患者的β-胶原降解产物、Ⅰ型前胶原N末端前肽均高于正常参考值;ARCOⅡ期、Ⅳ期患者的25-羟基维生素D低于正常参考值;⑤结论:股骨头坏死患者的骨代谢水平异常,不同病因、ARCO分期的股骨头坏死患者的β-胶原降解产物、Ⅰ型前胶原N末端前肽均高于正常参考值,处于高骨转换状态;β-胶原降解产物、Ⅰ型前胶原N末端前肽、骨钙素N端中分子片段可能是股骨头坏死发病的危险因素。